{"filing":{"accession_number":"0001213900-26-099435","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"ea0305391-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026099435/ea0305391-6k_radiopharm.htm"},"events":[{"id":33070,"run_id":30397,"accession_number":"0001213900-26-099435","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This announcement discloses positive interim Phase 2b clinical trial data for RAD101 (93% concordance with MRI, meeting primary endpoint) and selection for late-breaking oral presentation at SNO26, along with a planned FDA meeting to align on Phase 3 protocol. While the data is clinically significant and material to investors assessing the company's pipeline progress, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). This is a material clinical/regulatory milestone in drug development—an operational event reflecting advancement toward pivotal trials in a ~$600M addressable market.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36408,"accession_number":"0001213900-26-099435","item_number":"EX-99.1","item_title":"ea030539101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This announcement discloses positive interim Phase 2b clinical trial data for RAD101 (93% concordance with MRI, meeting primary endpoint) and selection for late-breaking oral presentation at SNO26, along with a planned FDA meeting to align on Phase 3 protocol. While the data is clinically significant and material to investors assessing the company's pipeline progress, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). This is a material clinical/regulatory milestone in drug development—an operational event reflecting advancement toward pivotal trials in a ~$600M addressable market.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:12:38.292403+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36408,"accession_number":"0001213900-26-099435","item_number":"EX-99.1","item_title":"ea030539101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This announcement discloses positive interim Phase 2b clinical trial data for RAD101 (93% concordance with MRI, meeting primary endpoint) and selection for late-breaking oral presentation at SNO26, along with a planned FDA meeting to align on Phase 3 protocol. While the data is clinically significant and material to investors assessing the company's pipeline progress, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). This is a material clinical/regulatory milestone in drug development—an operational event reflecting advancement toward pivotal trials in a ~$600M addressable market.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:12:38.292403+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-09-14"}]}